Year: 2015

Bristol’s drug pricing under fire as UK agency rejects Opdivo

Your Health Matters

Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence (NICE) said using Opdivo, or nivolumab, in non-small cell lung cancer after chemotherapy did not represent a cost-effective use of resources. “Recently we have seen drug companies setting very high prices for promising immunotherapies, including nivolumab,” said Paul Workman, chief executive of the Institute of Cancer Research.
Go to Source

British watchdog investigates Reckitt’s Nurofen Express ad

Your Health Matters

Nurofen pain relievers targeting specific types of pain are seen on a pharmacy shelf in Sydney(Reuters) – Britain's advertising watchdog is investigating whether a television ad for Reckitt Benckiser Group&039;s Nurofen Express pain relief tablets misled consumers with unfounded claims. The Advertising Standards Authority (ASA) said it received complaints in February that the ad was misleading because it implies the drug directly targets head muscles and gives faster headache relief than paracetamol or ibuprofen. Confirmation of the ASA investigation, which was launched in March, came a day after an Australian court said Reckitt had misled consumers by marketing identical products for different types of pain.

Go to Source

1 … 4 5 6 7 8 … 345